Longevity TV

Towards a consensus definition of biological aging

Attila Csordas, Founder & Director, AgeCurve Ltd.

Reversal of several aging pathways & diseases

George Church, Founding Core Faculty & Lead, Synthetic Biology, Wyss Institute at Harvard University.

Leveraging aging science (geroscience) to improve older adults’ immune health

Nir Barzilai, Director, Institute for Aging Research.

Connections & differences between different hallmark processes

Lynne Cox, Associate Professor in Biochemistry, University of Oxford.

The use of TORC1 inhibitors to improve immune function in the elderly

Joan Mannick, Chief Medical Officer, resTORbio

How do we show in humans that a drug targets aging?

Nir Barzilai, Director, Institute for Aging Research

Geroprotectors: time to change the way we treat older people?

Ilaria Bellantuono, Professor in Musculoskeletal Ageing, Co-Director, The Healthy Lifespan Institute, Department of Oncology and Metabolism

Interview with Margaretta Colangelo

Margaretta Colangelo, Co-founder / Managing Partner, Deep Knowledge Ventures / Longevity.Capital / Deep Knowledge Analytics

Applying AI approaches to diverse aging-related problems

Alexander Zhavoronkov, Chief Executive Officer, Insilico Medicine, Inc

Margaretta Colangelo in conversation with Richard Siow, John Shepherd, and Alexander Zhavoronkov

Margaretta Colangelo, Co-founder / Managing Partner, Deep Knowledge Ventures / Longevity.Capital / Deep Knowledge Analytics

The Big Picture: Covid-19 and Longevity investing

Jim Mellon, Chairman and Founder, Burnbrae Group

The view from the valley

Kate Batz, Managing Partner, Longevity Capital and Director of Strategy at Deep Knowledge Ventures and Aging Analytics Agency.

Accelerating agetech

Lorraine Morley, UK Lead / Advisor, AgeTech Accelerator

Longevity: Start now … Introduction

Johnny Adams, CEO / Executive Director, Aging Intervention Foundation; Executive Director, Gerontology Research Group

Rejuvant – starting Longevity now

Tom Weldon, Founder, Executive Chairman, Acting CEO, Ponce De Leon Health

How can BioViva address the here and now?

Liz Parrish, CEO, BioViva Sciences

Latest articles

Fountain’s ‘hypothesis-free’ approach to Longevity AI

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to...

G3 and Juvenescence partner on deep learning venture

G3 Therapeutics and Juvenescence announce the formation of Juvenomics to apply deep molecular profiling and deep learning to tackle aging. Juvenomics, a joint venture between...

Building an artificial immune system

DoD-funded ThirdLaw Technologies to harness the power of ‘spiroligomers’ to rapidly build new small molecules for Longevity therapies. Far from the world of stock market...

Neurotech is the new blue ocean

Alon Braun, Co-Founder, Neurotech Analytics.